Edge Therapeutics Stock Price, News & Analysis (NASDAQ:EDGE)

$15.72 +0.22 (+1.42 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$15.72
Today's Range$14.96 - $15.95
52-Week Range$7.30 - $15.95
Volume255,407 shs
Average Volume122,356 shs
Market Capitalization$485.11 million
P/E Ratio-10.08
Dividend YieldN/A
BetaN/A

About Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics logoEdge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company's product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company's product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

Receive EDGE News and Ratings via Email

Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:EDGE
CUSIPN/A
Phone800-208-3343

Debt

Debt-to-Equity Ratio0.20%
Current Ratio8.34%
Quick Ratio8.34%

Price-To-Earnings

Trailing P/E Ratio-10.0769230769231
Forward P/E Ratio-9.25
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.09 per share
Price / Book5.09

Profitability

Trailing EPS($1.56)
Net Income$-38,820,000.00
Net MarginsN/A
Return on Equity-56.88%
Return on Assets-43.74%

Miscellaneous

Employees31
Outstanding Shares30,860,000

Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics Inc (NASDAQ:EDGE) announced its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($0.37) EPS for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.11. View Edge Therapeutics' Earnings History.

When will Edge Therapeutics make its next earnings announcement?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Edge Therapeutics.

Where is Edge Therapeutics' stock going? Where will Edge Therapeutics' stock price be in 2018?

3 Wall Street analysts have issued 1 year price objectives for Edge Therapeutics' shares. Their predictions range from $17.00 to $30.00. On average, they expect Edge Therapeutics' stock price to reach $22.67 in the next year. View Analyst Ratings for Edge Therapeutics.

Who are some of Edge Therapeutics' key competitors?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the folowing people:

  • Sol J. Barer Ph.D., Independent Chairman of the Board (Age 69)
  • Brian A. Leuthner, President, Chief Executive Officer, Director (Age 52)
  • Isaac Blech, Independent Vice Chairman of the Board
  • Andrew Saik, Chief Financial Officer (Age 48)
  • Daniel Brennan, Chief Operating Officer (Age 49)
  • W. Bradford Middlekauff, Senior Vice President, General Counsel, Secretary (Age 55)
  • Alyssa J. S. Wyant, Senior Vice President, Regulatory Affairs (Age 42)
  • Albert N. Marchio II, Chief Accounting Officer, Chief Administrative Officer (Age 64)
  • R. Loch Macdonald M.D. Ph.D., Chief Scientific Officer, Director (Age 55)
  • Herbert J. Faleck, Chief Medical Officer (Age 64)

Who owns Edge Therapeutics stock?

Edge Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include VHCP Management II LLC (3.16%), BlackRock Inc. (3.06%), Eagle Asset Management Inc. (2.86%), Millennium Management LLC (0.90%), Regentatlantic Capital LLC (0.29%) and Schwab Charles Investment Management Inc. (0.29%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James Healy, James J Loughlin, R Loch Macdonald and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.

Who sold Edge Therapeutics stock? Who is selling Edge Therapeutics stock?

Edge Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Millennium Management LLC and Regentatlantic Capital LLC. Company insiders that have sold Edge Therapeutics company stock in the last year include Albert N Marchio II, Brian A Leuthner and R Loch Macdonald. View Insider Buying and Selling for Edge Therapeutics.

Who bought Edge Therapeutics stock? Who is buying Edge Therapeutics stock?

Edge Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Granite Investment Partners LLC, BlackRock Inc., SG Americas Securities LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Edge Therapeutics stock in the last two years include James Healy, James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.

How do I buy Edge Therapeutics stock?

Shares of Edge Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edge Therapeutics' stock price today?

One share of Edge Therapeutics stock can currently be purchased for approximately $15.72.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $485.11 million. The biotechnology company earns $-38,820,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. Edge Therapeutics employs 31 workers across the globe.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Dr Ste 4000, BERKELEY HEIGHTS, NJ 07922-2817, United States. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]


MarketBeat Community Rating for Edge Therapeutics (EDGE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Edge Therapeutics (NASDAQ:EDGE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.67$22.67$25.50$25.50
Price Target Upside: 112.63% upside112.63% upside171.28% upside171.28% upside

Edge Therapeutics (NASDAQ:EDGE) Consensus Price Target History

Price Target History for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ:EDGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$17.00HighView Rating Details
3/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$21.00N/AView Rating Details
3/3/2017GuggenheimReiterated RatingBuy -> In-Line$30.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$34.00 -> $18.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Edge Therapeutics (NASDAQ:EDGE) Earnings History and Estimates Chart

Earnings by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ EDGE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.44)N/AView Earnings Details
11/1/2017Q3 2017($0.48)($0.37)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.44)($0.44)ViewListenView Earnings Details
5/3/2017Q1 2017($0.42)($0.42)ViewListenView Earnings Details
3/2/2017Q4 2016($0.42)($0.33)ViewListenView Earnings Details
11/1/2016Q3 2016($0.38)($0.37)ViewN/AView Earnings Details
8/3/2016Q2($0.38)($0.33)ViewListenView Earnings Details
5/3/2016Q1 2016($0.34)($0.32)ViewListenView Earnings Details
3/8/2016Q4($0.32)($0.30)ViewListenView Earnings Details
11/6/2015Q315($0.23)($7.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Edge Therapeutics (NASDAQ:EDGE) Earnings Estimates

2018 EPS Consensus Estimate: ($2.11)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.55)($0.55)($0.55)
Q2 20181($0.52)($0.52)($0.52)
Q3 20181($0.51)($0.51)($0.51)
Q4 20181($0.53)($0.53)($0.53)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Edge Therapeutics (NASDAQ:EDGE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Edge Therapeutics (NASDAQ EDGE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 36.19%
Institutional Ownership Percentage: 49.21%
Insider Trades by Quarter for Edge Therapeutics (NASDAQ:EDGE)
Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Edge Therapeutics (NASDAQ EDGE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2018R. Loch MacdonaldInsiderSell2,500$14.49$36,225.00590,602View SEC Filing  
2/20/2018R. Loch MacdonaldInsiderSell5,000$13.75$68,750.00590,602View SEC Filing  
2/1/2018Brian A LeuthnerCEOSell2,500$13.14$32,850.0082,736View SEC Filing  
1/3/2018Brian A LeuthnerInsiderSell5,000$10.11$50,550.0087,736View SEC Filing  
12/5/2017Brian A LeuthnerInsiderSell7,500$9.86$73,950.0095,236View SEC Filing  
12/1/2017Brian A LeuthnerCEOSell2,500$9.92$24,800.0095,236View SEC Filing  
11/22/2017Albert N. Marchio IIInsiderSell3,361$10.00$33,610.00View SEC Filing  
11/3/2017Brian A LeuthnerInsiderSell7,500$10.91$81,825.00102,736View SEC Filing  
11/1/2017Brian A LeuthnerCEOSell2,500$10.92$27,300.00102,736View SEC Filing  
10/4/2017Brian A LeuthnerInsiderSell7,500$10.96$82,200.00View SEC Filing  
10/3/2017Brian A LeuthnerCEOSell2,500$10.93$27,325.00110,236View SEC Filing  
10/2/2017Brian A LeuthnerCEOSell2,500$10.81$27,025.00110,236View SEC Filing  
9/6/2017Brian A LeuthnerInsiderSell7,500$10.21$76,575.00117,736View SEC Filing  
9/5/2017Brian A LeuthnerCEOSell2,500$9.94$24,850.00117,736View SEC Filing  
9/1/2017Brian A LeuthnerCEOSell2,500$10.37$25,925.00117,736View SEC Filing  
8/29/2017Albert N Marchio IIInsiderSell2,500$10.42$26,050.003,361View SEC Filing  
8/23/2017Albert N Marchio IIInsiderSell1,000$10.39$10,390.005,861View SEC Filing  
8/3/2017Brian A LeuthnerInsiderSell7,500$10.53$78,975.00125,236View SEC Filing  
7/6/2017Brian A LeuthnerInsiderSell7,500$10.19$76,425.00132,736View SEC Filing  
3/6/2017James J LoughlinDirectorBuy3,000$9.24$27,720.0019,625View SEC Filing  
2/7/2017Brian A LeuthnerInsiderSell1,500$9.52$14,280.00245,479View SEC Filing  
2/6/2017Brian A LeuthnerInsiderSell3,000$9.61$28,830.00248,479View SEC Filing  
2/2/2017Brian A LeuthnerInsiderSell3,000$9.50$28,500.00251,479View SEC Filing  
12/1/2016Brian A LeuthnerInsiderSell7,500$11.60$87,000.00252,979View SEC Filing  
10/3/2016Brian A LeuthnerInsiderSell7,500$10.25$76,875.00260,479View SEC Filing  
8/8/2016W Bradford MiddlekauffVPBuy10,000$9.48$94,800.009,857View SEC Filing  
8/1/2016Brian A LeuthnerInsiderSell7,500$9.54$71,550.00267,979View SEC Filing  
3/11/2016James HealyDirectorBuy541,343$7.30$3,951,803.90View SEC Filing  
10/6/2015Andrew J. EinhornCFOBuy45,000$11.00$495,000.0041,656View SEC Filing  
10/6/2015James HealyDirectorBuy450,000$11.00$4,950,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Edge Therapeutics (NASDAQ EDGE) News Headlines

Source:
DateHeadline
Applied Therapeutics Announces Support for Rare Disease Day 2018Applied Therapeutics Announces Support for Rare Disease Day 2018
www.bizjournals.com - February 23 at 5:07 PM
Edge Therapeutics Inc (EDGE) Insider Sells $36,225.00 in StockEdge Therapeutics Inc (EDGE) Insider Sells $36,225.00 in Stock
www.americanbankingnews.com - February 22 at 7:26 PM
Insider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 5,000 Shares of StockInsider Selling: Edge Therapeutics Inc (EDGE) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - February 22 at 7:08 PM
Edge Therapeutics (EDGE) Scheduled to Post Earnings on WednesdayEdge Therapeutics (EDGE) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:22 AM
Zacks: Analysts Set $21.00 Target Price for Edge Therapeutics Inc (EDGE)Zacks: Analysts Set $21.00 Target Price for Edge Therapeutics Inc (EDGE)
www.americanbankingnews.com - February 19 at 7:34 AM
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
www.zacks.com - February 7 at 9:23 AM
 Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.47 Earnings Per Share Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce -$0.47 Earnings Per Share
www.americanbankingnews.com - February 4 at 1:18 AM
Form 4 Edge Therapeutics, Inc. For: Feb 01 Filed by: Leuthner Brian AForm 4 Edge Therapeutics, Inc. For: Feb 01 Filed by: Leuthner Brian A
www.streetinsider.com - February 3 at 4:21 PM
Insider Selling: Edge Therapeutics Inc (EDGE) CEO Sells 2,500 Shares of StockInsider Selling: Edge Therapeutics Inc (EDGE) CEO Sells 2,500 Shares of Stock
www.americanbankingnews.com - February 3 at 12:16 AM
RISE Research and Constance Therapeutics Announce Comprehensive Strategic PartnershipRISE Research and Constance Therapeutics Announce Comprehensive Strategic Partnership
www.finanznachrichten.de - January 30 at 4:18 PM
Bigger Bubble: Cannabis or Cryptocurrencies? It’s Looking Like Cannabis Has the EdgeBigger Bubble: Cannabis or Cryptocurrencies? It’s Looking Like Cannabis Has the Edge
www.fool.ca - January 29 at 9:28 AM
Biotech Deals Are Costly. So Are In-House Clinical FailuresBiotech Deals Are Costly. So Are In-House Clinical Failures
www.bloomberg.com - January 26 at 4:16 PM
Biogen earnings: The art of the (expected) dealBiogen earnings: The art of the (expected) deal
www.marketwatch.com - January 24 at 9:49 AM
Celgene buying Juno for $9 billion in cancer drug betCelgene buying Juno for $9 billion in cancer drug bet
www.msn.com - January 22 at 6:00 PM
Edge Therapeutics (EDGE) Earns Outperform Rating from Credit Suisse GroupEdge Therapeutics (EDGE) Earns Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - January 21 at 6:22 PM
Edge Therapeutics (EDGE) Upgraded to Hold at BidaskClubEdge Therapeutics (EDGE) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - January 20 at 11:12 AM
 Analysts Anticipate Edge Therapeutics Inc (EDGE) Will Post Earnings of -$0.47 Per Share Analysts Anticipate Edge Therapeutics Inc (EDGE) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - January 18 at 3:06 AM
 Brokerages Set $21.00 Target Price for Edge Therapeutics Inc (EDGE) Brokerages Set $21.00 Target Price for Edge Therapeutics Inc (EDGE)
www.americanbankingnews.com - January 15 at 5:08 PM
Edge Therapeutics (EDGE) Stock Rating Upgraded by BidaskClubEdge Therapeutics (EDGE) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 15 at 12:44 AM
Beverly A. Huss Joins Accuray Board of DirectorsBeverly A. Huss Joins Accuray Board of Directors
www.bizjournals.com - January 11 at 4:57 PM
Edges EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility AnalysisEdge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
finance.yahoo.com - December 29 at 4:46 PM
Edge Therapeutics (EDGE) vs. Its Competitors Head-To-Head SurveyEdge Therapeutics (EDGE) vs. Its Competitors Head-To-Head Survey
www.americanbankingnews.com - December 27 at 3:54 PM
Head to Head Comparison: Edge Therapeutics (EDGE) and Its RivalsHead to Head Comparison: Edge Therapeutics (EDGE) and Its Rivals
www.americanbankingnews.com - December 26 at 1:34 PM
Edge Therapeutics (EDGE) & Its Peers Critical ReviewEdge Therapeutics (EDGE) & Its Peers Critical Review
www.americanbankingnews.com - December 26 at 1:34 PM
Reviewing Edge Therapeutics (EDGE) and Its RivalsReviewing Edge Therapeutics (EDGE) and Its Rivals
www.americanbankingnews.com - December 26 at 11:30 AM
Form 6-K Aptose Biosciences Inc. For: Dec 26Form 6-K Aptose Biosciences Inc. For: Dec 26
www.streetinsider.com - December 26 at 9:12 AM
Critical Review: Edge Therapeutics (EDGE) vs. The CompetitionCritical Review: Edge Therapeutics (EDGE) vs. The Competition
www.americanbankingnews.com - December 22 at 3:50 PM
Critical Survey: Edge Therapeutics (EDGE) and Its CompetitorsCritical Survey: Edge Therapeutics (EDGE) and Its Competitors
www.americanbankingnews.com - December 19 at 9:34 PM
Brokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce ($0.47) Earnings Per ShareBrokerages Anticipate Edge Therapeutics Inc (EDGE) to Announce ($0.47) Earnings Per Share
www.americanbankingnews.com - December 19 at 7:14 AM
Critical Review: Edge Therapeutics (EDGE) vs. Its CompetitorsCritical Review: Edge Therapeutics (EDGE) vs. Its Competitors
www.americanbankingnews.com - December 19 at 1:26 AM
Analyzing Edge Therapeutics (EDGE) & Its PeersAnalyzing Edge Therapeutics (EDGE) & Its Peers
www.americanbankingnews.com - December 19 at 1:26 AM
Analyzing Edge Therapeutics (EDGE) and Its RivalsAnalyzing Edge Therapeutics (EDGE) and Its Rivals
www.americanbankingnews.com - December 18 at 3:28 AM
Edge Therapeutics (EDGE) vs. Its Competitors Critical AnalysisEdge Therapeutics (EDGE) vs. Its Competitors Critical Analysis
www.americanbankingnews.com - December 14 at 7:16 AM
Edge Therapeutics (EDGE) Downgraded to Strong Sell at BidaskClubEdge Therapeutics (EDGE) Downgraded to Strong Sell at BidaskClub
www.americanbankingnews.com - December 12 at 11:34 PM
Life-Shortening Blood Disease Gets Rush of ResearchLife-Shortening Blood Disease Gets Rush of Research
www.bloomberg.com - December 12 at 10:31 AM
Reviewing Edge Therapeutics (EDGE) and Its PeersReviewing Edge Therapeutics (EDGE) and Its Peers
www.americanbankingnews.com - December 10 at 3:30 PM
Edge Therapeutics Inc (EDGE) CEO Sells $24,800.00 in StockEdge Therapeutics Inc (EDGE) CEO Sells $24,800.00 in Stock
www.americanbankingnews.com - December 5 at 10:26 PM
Edge Therapeutics Inc (EDGE) Insider Sells $73,950.00 in StockEdge Therapeutics Inc (EDGE) Insider Sells $73,950.00 in Stock
www.americanbankingnews.com - December 5 at 9:52 PM
 Edge Therapeutics Inc (EDGE) Receives Consensus Recommendation of "Strong Buy" from Brokerages Edge Therapeutics Inc (EDGE) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 4 at 11:48 AM
Zacks: Brokerages Anticipate Edge Therapeutics, Inc. (EDGE) to Post -$0.47 Earnings Per ShareZacks: Brokerages Anticipate Edge Therapeutics, Inc. (EDGE) to Post -$0.47 Earnings Per Share
www.americanbankingnews.com - November 27 at 7:48 AM
Albert N. Marchio II Sells 3,361 Shares of Edge Therapeutics, Inc. (EDGE) StockAlbert N. Marchio II Sells 3,361 Shares of Edge Therapeutics, Inc. (EDGE) Stock
www.americanbankingnews.com - November 22 at 4:54 PM
Brokerages Anticipate Edge Therapeutics, Inc. (EDGE) to Announce ($0.47) Earnings Per ShareBrokerages Anticipate Edge Therapeutics, Inc. (EDGE) to Announce ($0.47) Earnings Per Share
www.americanbankingnews.com - November 18 at 7:24 PM
Edge Therapeutics (EDGE) and Affimed N.V. (AFMD) Head-To-Head ComparisonEdge Therapeutics (EDGE) and Affimed N.V. (AFMD) Head-To-Head Comparison
www.americanbankingnews.com - November 18 at 3:37 AM
Mid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q4 ExpectationsMid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q4 Expectations
www.nasdaq.com - November 13 at 11:45 AM
Zacks Investment Research Upgrades Edge Therapeutics, Inc. (EDGE) to "Buy"Zacks Investment Research Upgrades Edge Therapeutics, Inc. (EDGE) to "Buy"
www.americanbankingnews.com - November 6 at 11:36 PM
Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare ConferenceEdge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
finance.yahoo.com - November 6 at 7:36 PM
FY2017 EPS Estimates for Edge Therapeutics, Inc. Raised by Leerink Swann (EDGE)FY2017 EPS Estimates for Edge Therapeutics, Inc. Raised by Leerink Swann (EDGE)
www.americanbankingnews.com - November 6 at 6:14 AM
Edge Therapeutics, Inc. (EDGE) CEO Sells $27,300.00 in StockEdge Therapeutics, Inc. (EDGE) CEO Sells $27,300.00 in Stock
www.americanbankingnews.com - November 3 at 9:44 PM
Insider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 7,500 Shares of StockInsider Selling: Edge Therapeutics, Inc. (EDGE) Insider Sells 7,500 Shares of Stock
www.americanbankingnews.com - November 3 at 9:24 PM
Obalon Therapeutics, Inc. And Sono Bello Announce Agreement To Offer Novel Weight Loss Treatment In Sono Bello CentersObalon Therapeutics, Inc. And Sono Bello Announce Agreement To Offer Novel Weight Loss Treatment In Sono Bello Centers
www.thestreet.com - November 3 at 1:20 PM

SEC Filings

Edge Therapeutics (NASDAQ:EDGE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Edge Therapeutics (NASDAQ:EDGE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Edge Therapeutics (NASDAQ EDGE) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.